Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Oklo Inc (OKLO) Price & Performance

ACADIA Pharmaceuticals Inc.Trade

Oklo IncTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs Oklo Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.19 (market cap $5.07B), while Oklo Inc trades at $46.14 (market cap $8.74B). The key difference: Oklo Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals.

	ACAD	OKLO
Market Cap	$5.07B	$8.74B
Sector	Health	Technology
52-Week High	$29.41	$174.14
52-Week Low	$20.06	$36.84
Enterprise Value	$4.19B	$6.28B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.

Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.

Oklo Inc

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ACAD

Immunic appoints Elena Ridloff to board ahead of key Phase 3 MS trial data and potential commercialization.PRNewsWire · 1 day agoBullish ACADIA Pharmaceuticals beats Q2 earnings and revenue estimates, raising 2026 revenue forecast and price target.Andrew Wynn · 2 days agoBullish View details →

OKLO

NuScale Power shares fall 32% YTD amid revenue drop and dilution, awaiting key contracts to rebound.24/7 Wall Street · 23 hours agoBearish Oklo posts first revenue with reactor milestone; AST SpaceMobile reports higher revenue but heavy launch loss.24/7 Wall Street · 1 day agoNeutral Oklo posts $1.2M Q2 revenue with 14% stock rise, but core tech validation and cost clarity remain uncertain.Seeking Alpha · 4 days agoNeutral View details →

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

About Oklo Inc

Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.